Abortion pill creators file emergency appeal with Supreme Court
The makers of the abortion pill mifepristone have filed an emergency appeal at the Supreme Court urging the justices to pause a lower-court ruling that temporarily blocked Americans from accessing the drug through the mail, reports BritPanorama.
This expedited case, submitted to conservative Justice Samuel Alito, brings the issue of mifepristone back to the Supreme Court less than two years after a similar challenge was dismissed, which allowed the pill to remain widely accessible.
The appeal was filed shortly after the 5th US Circuit Court of Appeals reinstated a nationwide requirement that the medication must be obtained in person. This move significantly undermines access to a method of abortion that has increased in popularity since the Supreme Court overturned Roe v. Wade, the 1973 ruling that enshrined a constitutional right to abortion.
In its appeal, Danco Laboratories stated that the lower-court ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” The company’s attorneys highlighted potential issues patients may face, including confusion over appointments or obtaining prescriptions in various states.
Danco has requested that the Supreme Court issue an “administrative” stay to immediately pause the 5th Circuit’s decision, while urging the court to take up the case based on its merits.
Since the Covid-19 pandemic, women have been able to obtain mifepristone—the first of two drugs used in medication abortions—via telehealth appointments. The Biden administration implemented regulations in 2023 ending the necessity of in-person visits to obtain the medication following the Supreme Court’s decision to overturn Roe.
As many conservative states have moved to ban or restrict access to clinic abortions in response, medication abortions have become increasingly prevalent. Research from the Guttmacher Institute indicates that medication abortions constituted over 60% of total abortions in the US in 2023.
In 2024, Louisiana filed a lawsuit claiming that the Biden-era regulation undermined its own abortion bans, but a federal district court determined in April not to restrict access to the drug while the FDA conducted a safety review.
Analysis has shown that mifepristone is largely safe, with fewer reported side effects compared to various commonly used medications.
This judicial scrutiny highlights ongoing tensions surrounding abortion rights and access in the United States, continuing a contentious debate over reproductive health policy.
